{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:11:06Z","timestamp":1790647866093,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024491","name":"University Institute for Addictions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007671","name":"Foundation of CHUM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neubiorev.2026.106910","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:34:11Z","timestamp":1787236451000},"page":"106910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Does co-administration of cannabidiol (CBD) influence the plasma availability of delta-9-tetrahydrocannabinol (THC) and its active metabolite in humans? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-0281","authenticated-orcid":false,"given":"Lucy A.","family":"Chester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidar","family":"Sharafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Mahroug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Olivier","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13125","article-title":"Sex differences in acute cannabis effects revisited: results from two randomized, controlled trials","volume":"27","author":"Arkell","year":"2021","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib2","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","article-title":"Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition","author":"Arkell","year":"2019","journal-title":"Psychopharmacol. Psychopharmacol."},{"issue":"21","key":"10.1016\/j.neubiorev.2026.106910_bib3","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/jama.2020.21218","article-title":"Effect of cannabidiol and delta-9-tetrahydrocannabinol on driving performance: a randomized clinical trial","volume":"324","author":"Arkell","year":"2020","journal-title":"JAMA - J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03242-7","article-title":"Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats","volume":"11","author":"Baglot","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2026.106910_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","author":"Bansal","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106910_bib6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/17512433.2022.2148655","article-title":"Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy","volume":"15","author":"Bardhi","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib7","first-page":"1","article-title":"The endocannabinoid system: an overview","author":"Battista","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neubiorev.2026.106910_bib8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u03b4-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.neubiorev.2026.106910_bib9","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/01.WNL.0000031422.66442.49","article-title":"Dose-related neurocognitive effects of marijuana use","volume":"59","author":"Bolla","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neubiorev.2026.106910_bib10","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2011"},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106910_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J. Med. Libr. Assoc."},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106910_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220025","article-title":"Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study","volume":"14","author":"Chung","year":"2019","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2024-301027","article-title":"Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers","volume":"27","author":"Couttas","year":"2024","journal-title":"BMJ Ment. Health"},{"key":"10.1016\/j.neubiorev.2026.106910_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2215-0366(17)30075-5","article-title":"Can we make cannabis safer?","volume":"4","author":"Englund","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2026.106910_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2026.106910_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios","volume":"48","author":"Englund","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2026.106910_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103381","article-title":"Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update","volume":"99","author":"Fischer","year":"2022","journal-title":"Int. J. Drug. Policy"},{"key":"10.1016\/j.neubiorev.2026.106910_bib18","unstructured":"Food and Drug Administration. M12 Drug Interaction Studies. In.: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2024."},{"key":"10.1016\/j.neubiorev.2026.106910_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: A simulation study","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3381","article-title":"Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of \u03949-Tetrahydrocannabinol Without Improving Its Analgesic Properties","author":"Gorbenko","year":"2024","journal-title":"Clin. Pharmacol. & Ther."},{"key":"10.1016\/j.neubiorev.2026.106910_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/09595230310001613976","article-title":"Being stoned: A review of self-reported cannabis effects","volume":"22","author":"Green","year":"2003","journal-title":"Drug. Alcohol. Rev."},{"key":"10.1016\/j.neubiorev.2026.106910_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.neubiorev.2026.106910_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1300\/J175v03n03_03","volume":"3","author":"Guy","year":"2004","journal-title":"J. Cannabis Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106910_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1300\/J175v03n04_02","article-title":"A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)","volume":"3","author":"Guy","year":"2004","journal-title":"J. Cannabis Ther."},{"key":"10.1016\/j.neubiorev.2026.106910_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103716","article-title":"Trends in the use of cannabis products in Canada and the USA, 2018 - 2020: Findings from the International Cannabis Policy Study","volume":"105","author":"Hammond","year":"2022","journal-title":"Int. J. Drug. Policy"},{"key":"10.1016\/j.neubiorev.2026.106910_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: A unified critical inventory","author":"Hanu\u0161","year":"2016","journal-title":"Nat. Product. Rep."},{"key":"10.1016\/j.neubiorev.2026.106910_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2026.108508","article-title":"Increasing use of cannabis edibles in response to recreational cannabis legalization in the United States","author":"Hawkins","year":"2026","journal-title":"Prev. Med."},{"key":"10.1016\/j.neubiorev.2026.106910_bib29","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 64 (updated August 2023)","article-title":"Chapter 23: Including variants on randomized trials","author":"Higgins","year":"2023"},{"key":"10.1016\/j.neubiorev.2026.106910_bib30","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","year":"2024"},{"key":"10.1016\/j.neubiorev.2026.106910_bib31","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]","author":"Higgins","year":"2024"},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106910_bib32","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.euroneuro.2017.10.037","article-title":"Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC","volume":"27","author":"Hlo\u017eek","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib33","first-page":"3","article-title":"Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol","volume":"11","author":"Hollister","year":"1974","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2026.106910_bib34","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1089\/can.2023.0117","article-title":"Cannabidiol oil ingested as sublingual drops or within gelatin capsules shows similar pharmacokinetic profiles in healthy males","volume":"9","author":"Johnson","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","article-title":"Cannabidiol potentiates \u03949-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats","volume":"218","author":"Klein","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2026.106910_bib36","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106910_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/add.16154","article-title":"The acute effects of cannabis with and without cannabidiol in adults and adolescents: a randomised, double-blind, placebo-controlled, crossover experiment","volume":"118","author":"Lawn","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2026.106910_bib38","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.neubiorev.2026.106910_bib39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/0024-3205(85)90376-5","article-title":"Structural requirements for cannabinoid-induced antinociceptive activity in mice","volume":"36","author":"Martin","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.neubiorev.2026.106910_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","article-title":"Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of d9 -tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract","volume":"27","author":"Nadulski","year":"2005","journal-title":"Ther. Drug. Monit."},{"issue":"8","key":"10.1016\/j.neubiorev.2026.106910_bib42","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jat\/29.8.782","article-title":"Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract","volume":"29","author":"Nadulski","year":"2005","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib43","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: Identification of recent cannabis intake","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neubiorev.2026.106910_bib44","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.neubiorev.2026.106910_bib45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neubiorev.2026.106910_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","article-title":"-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","author":"Pertwee","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib47","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.3390\/ijms24065251","article-title":"THC and CBD: Villain versus Hero? Insights into Adolescent Exposure","volume":"24","author":"Pintori","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neubiorev.2026.106910_bib48","article-title":"Oral Administration of Cannabis and \u0394-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review","volume":"56","author":"Poyatos","year":"2020","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.neubiorev.2026.106910_bib49","unstructured":"Public Health Agency of Canada. Canada\u2019s Lower-Risk Cannabis Use Guidelines (LRCUG). In.; 2019."},{"issue":"15","key":"10.1016\/j.neubiorev.2026.106910_bib50","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1021\/acschemneuro.5c00417","article-title":"Predicting \u0394-9-Tetrahydrocannabinol-Induced Psychoactive and Cognitive Effects: A PBPK-PD Approach to Quantifying Feeling High and Reduced Alertness","volume":"16","author":"Qian","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neubiorev.2026.106910_bib51","series-title":"Pharmaceutics","first-page":"237","article-title":"Quantifying heart rate changes after delta-9-tetrahydrocannabinol administration using a PBPK-PD model in healthy adults","author":"Qian","year":"2025"},{"key":"10.1016\/j.neubiorev.2026.106910_bib52","unstructured":"Rohatgi A. WebPlotDigitizer. Version 5.2. Accessed: 02 Apr 2025. Available from: https:\/\/automeris.io."},{"issue":"12","key":"10.1016\/j.neubiorev.2026.106910_bib53","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00213-021-05976-8","article-title":"Pharmacokinetic and pharmacodynamic properties of aerosolized (\"vaped\") THC in adolescent male and female rats","volume":"238","author":"Ruiz","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol","volume":"66","author":"Russo","year":"2006","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.neubiorev.2026.106910_bib55","series-title":"The GRADE Handbook","author":"Sch\u00fcnemann","year":"2013"},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106910_bib56","first-page":"149","article-title":"Chemistry, metabolism, and toxicology of cannabis: clinical implications","volume":"7","author":"Sharma","year":"2012","journal-title":"Iran. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106910_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12968","article-title":"Sex differences in the acute effects of oral and vaporized cannabis among healthy adults","volume":"26","author":"Sholler","year":"2021","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","author":"Showalter","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106910_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/phar.2512","article-title":"Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies","volume":"41","author":"Silmore","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/03602532.2024.2346767","article-title":"Effects of cannabidiol and \u03949-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review","volume":"56","author":"Smith","year":"2024","journal-title":"Drug. Metab. Rev."},{"key":"10.1016\/j.neubiorev.2026.106910_bib61","series-title":"European Archives of Psychiatry and Clinical Neuroscience","first-page":"17","article-title":"A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","author":"Solowij","year":"2019"},{"key":"10.1016\/j.neubiorev.2026.106910_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","article-title":"Changing landscape of cannabis: novel products, formulations, and methods of administration","volume":"30","author":"Spindle","year":"2019","journal-title":"Curr. Opin. Psychol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib63","unstructured":"StataCorp.Stata Statistical Software: Release 19."},{"key":"10.1016\/j.neubiorev.2026.106910_bib64","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-025-02232-x","article-title":"Effect of caffeine and cannabidiol (CBD) co-administration on \u03949-tetrahydrocannabinol (\u03949-THC) subjective effects, performance impairment, and pharmacokinetics","author":"Strickland","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106910_bib67","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881108089870","article-title":"Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids","volume":"22","author":"Strougo","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2026.106910_bib68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2026.106910_bib69","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical Studies on Drug\u2013Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2026.106910_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00213-002-1033-2","article-title":"Comparison of the subjective effects of \u03949-tetrahydrocannabinol and marijuana in humans","volume":"161","author":"Wachtel","year":"2002","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.neubiorev.2026.106910_bib71","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0269881119841568","article-title":"Dissociable effects of cannabis with and without cannabidiol on the human brain\u2019s resting-state functional connectivity","volume":"33","author":"Wall","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2026.106910_bib72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0022-3565(25)10720-9","article-title":"Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice","volume":"262","author":"Welch","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2026.106910_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.576877","article-title":"Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: a double-blind, placebo-controlled, randomized experimental trial in healthy volunteers","volume":"11","author":"Woelfl","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/jpet.123.001998","article-title":"The intoxication equivalency of 11-hydroxy-\u0394(9)-tetrahydrocannabinol relative to \u0394(9)-tetrahydrocannabinol","volume":"391","author":"Zagzoog","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2026.106910_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered delta9-tetrahydrocannabinol when coadministered with cannabidiol on delta9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.neubiorev.2026.106910_bib76","series-title":"Search strategy for Does Co-administration of Cannabidiol Influence the Plasma Availability of Delta-9-tetrahydrocannabinol in Humans? A Systematic Review and Meta-analysis","author":"Ziegler","year":"2024"}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763426003672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763426003672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:37:53Z","timestamp":1790257073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763426003672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"alternative-id":["S0149763426003672"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106910","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does co-administration of cannabidiol (CBD) influence the plasma availability of delta-9-tetrahydrocannabinol (THC) and its active metabolite in humans? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2026.106910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106910"}}